Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Obsidian TherapeuticsOBX -0.35%11 EPS without NRI is $-124.41 as of Jun. 2026. GuruFocus rates OBX with a GF Score™ of 11/100. The stock has 1 warning sign investors should review. Among 1,155 Biotechnology companies, Obsidian Therapeutics ranks worse than 86580% on this metric.
Obsidian Therapeutics's earnings per share without non-recurring items for the
three
months ended in Jun. 2026 was $-237.20.
Its earnings per share without non-recurring items for the trailing twelve months (TTM) ended in Jun. 2026 was $-124.41.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the EPS without NRI Growth Rate using Earnings per share without Non-Recurring Items (NRI) data.
The historical rank and industry rank for Obsidian Therapeutics's EPS without NRI or its related term are showing as below:
OBX's 3-Year EPS without NRI Growth Rate is not ranked *
in the Biotechnology industry.
Industry Median: 16 * Ranked among companies with meaningful 3-Year EPS without NRI Growth Rate only.
Obsidian Therapeutics's EPS (Basic) for the
three
months ended in Jun. 2026 was $-237.20.
Its EPS (Basic) for the trailing twelve months (TTM) ended in Jun. 2026 was $161.87.
Obsidian Therapeutics (NAS:OBX) EPS without NRI Explanation
EPS without NRI removes onetime and unusual items from EPS, to provide investors with a more accurate measure of the company’s true earnings. The earnings are adjusted for items that are irregular or unusual in nature, and/or are non-recurring. This is calculated using Net Income (Continuing Operations) plus/minus any tax affected unusual Items and Goodwill Impairments/Write Offs. This can be used to fairly measure a company's profitability.
Be Aware
Compared with Earnings per share, a company's cash flow is better indicator of the company's earnings power.
If a company's earnings per share is less than cash flow per share over long term, investors need to be cautious and find out why.
Obsidian Therapeutics EPS without NRI Related Terms
Obsidian Therapeutics EPS without NRI Historical Data
* Premium members only.
The historical data trend for Obsidian Therapeutics's EPS without NRI can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
OBX vs LXRX, SLNCF, ABUS: EPS without NRI Comparison
For the Biotechnology subindustry, Obsidian Therapeutics's PE Ratio without NRI, along with its competitors' market caps and PE Ratio without NRI data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Obsidian Therapeutics PE Ratio without NRI vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Obsidian Therapeutics's PE Ratio without NRI distribution charts can be found below:
* The bar in red indicates where Obsidian Therapeutics's PE Ratio without NRI falls into.
Earnings Per Share (EPS) is the single most important variable used by Wall Street in determining the earnings power of a company. But investors need to be aware that Earnings per Share can be easily manipulated by adjusting depreciation and amortization rate or non-recurring items. That's why GuruFocus lists EPS without NRI, which better reflects the company's underlying performance.
Earnings Per Share without Non-Recurring Items is the amount of earnings without non-recurring items per outstanding share of the company's stock.
EPS without NRI for the trailing twelve months (TTM) ended in Jun. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $-124.41
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Obsidian Therapeutics (OBX) has a EPS without NRI of $-124.41 as of Jun. 2026. EPS without NRI represents per-share earnings excluding one-time charges. View historical data on Obsidian Therapeutics and its competitors. According to the industry distribution chart, Obsidian Therapeutics ranks #999999 out of 1155 companies in the Biotechnology industry.
Is Obsidian Therapeutics' EPS without NRI too high?
Obsidian Therapeutics' current EPS without NRI is $-124.41. Based on the distribution chart, Obsidian Therapeutics ranks #999999 out of 1155 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, Obsidian Therapeutics has a GF Score™ of 11/100, reflecting its overall financial health beyond just this single metric.
How does Obsidian Therapeutics' EPS without NRI compare to LXRX and SLNCF?
According to the Biotechnology industry distribution chart, Obsidian Therapeutics ranks #999999 out of 1155 companies for EPS without NRI. This places Obsidian Therapeutics in the lower half of its industry. The industry median EPS without NRI is 16.00. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EPS without NRI for a Biotechnology company?
The median EPS without NRI among Biotechnology companies is 16.00, based on 1,155 companies in the industry. Companies in the top quartile (top 25%) have a EPS without NRI significantly above this median, while those in the bottom quartile fall well below. However, EPS without NRI should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EPS without NRI mean?
A high EPS without NRI can signal that a stock is expensive relative to its fundamentals. EPS without NRI represents per-share earnings excluding one-time charges. View historical data on Obsidian Therapeutics and its competitors. For the Biotechnology industry, the median EPS without NRI is 16.00 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Obsidian Therapeutics's current EPS without NRI is $-124.41. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Obsidian Therapeutics stock overvalued right now?
Obsidian Therapeutics (OBX) has a current EPS without NRI of $-124.41. The current EPS without NRI is $-124.41. Obsidian Therapeutics' overall GF Score™ is 11/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EPS without NRI calculated?
EPS without NRI is calculated from a company's financial statements. For Obsidian Therapeutics (OBX), the current EPS without NRI is $-124.41 as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Obsidian Therapeutics Inc is a clinical-stage biopharmaceutical company based in the United States that develops engineered cell therapies for solid tumors. The company's proprietary cytoDRiVE platform uses drug-responsive domains to regulate protein function, and its lead programs apply this technology to engineered tumor-infiltrating lymphocyte (TIL) therapies, known as cytoTILs. Its main product candidate, OBX-115, is an autologous, genetically engineered TIL therapy designed to eliminate the need for systemic interleukin-2 administration, and it is being evaluated in clinical trials for melanoma and non-small cell lung cancer. Obsidian also pursues additional engineered cell therapy programs built on its platform. The company operates as a research and development-stage business, funding its activities primarily through equity financing, partnerships, and collaboration arrangements rather than product revenue, and it targets oncology markets in the United States and other regions.
11GF Score
Get the complete analysis for OBX
EPS without NRI is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
OBX has been successfully added to your 
